Electromed (ELMD) Q1 2027 earnings summary

Executive summary

• Q1 FY2027 revenue rose 10.6% to $18.682M and operating income increased 30.7% to $3.489M, extending the YoY growth streak to 16 consecutive quarters.

• Direct homecare growth, higher sales-representative headcount and productivity, and stronger gross margin supported operating leverage.

Financial highlights

• Net revenue was $18.682M versus $16.887M; gross profit was $14.937M versus $13.197M.

• Operating income was $3.489M versus $2.7M; net income was $2.761M versus $2.1M; diluted EPS was $0.32 versus $0.25.

• SG&A increased 8.6% to $11.171M, primarily on higher sales-force salaries, incentives, travel and compensation; R&D rose 14.9% to $277K.

• Net cash provided by operations was $373K versus $0.2M in the year-ago quarter.

Outlook and guidance

• FY2027 target for annualized homecare revenue per weighted-average direct representative was $1.05M–$1.15M; Q1 was $1.109M.

• Management expects elevated DME inventory pressure to ease and distributor revenue to begin normalizing at the start of calendar 2027.

• Growth priorities include expanding the sales force and payer contracts, developing the market, and pursuing pediatric and hospital adjacencies; potential acquisitions remain under consideration.

• CEO Jim Cunniff expects to retire in April 2027; board succession planning is underway.